19 completed, 4 recruiting, 2 terminated, 2 unknown. 19 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 14, Recruiting 3, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow Endometrial Stromal Tumors: new trials by email Literature Review of Endometrial Stromal Tumors trials Research Report on Endometrial Stromal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-03-25 | 2026-05-22 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Prognosis of Low-grade Endometrial Stromal Sarcoma Surgical treatment with and without fertility-sparing procedures - Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis), Fertility-sparing Surgery | Unknown | Lei Li | 1000 | 2022-03-26 | 2022-04-04 | |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients Selinexor - Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 | Completed | University Health Network, Toronto | 56 | 2021-03-29 | 2025-05-29 |
| FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study Fulvestrant - Endometrial Stromal Sarcoma, Adenosarcoma of Uterus | Phase 2 | Completed | Frederic Amant | 17 | 2019-03-13 | 2024-05-28 |
| Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) Aromatase Inhibitors - Low Grade Endometrial Stromal Sarcoma | Phase 2 | Recruiting | Centre Leon Berard | 40 | 2019-01-23 | 2026-02-17 |
| Vorinostat (SAHA) in Uterine Sarcoma Vorinostat Oral Capsule - Leiomyosarcoma, Endometrial Stromal Tumors | Phase 2 | Terminated | Medical University of Graz | 3 | 2017-12-14 | 2020-08-04 |
| Observational Study on Endometrial Stromal Tumors Treatment for EST - Endometrial Stromal Tumors | Recruiting | Italian Sarcoma Group | 100 | 2016-10-01 | 2026-01-02 | |
| Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram - Adrenocortical Adenoma, Endometrial Stromal Sarcomas | Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2014-08-01 | 2016-12-05 |
| Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Trebananib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 35 | 2011-06-06 | 2018-02-23 |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer cyproheptadine hydrochloride, placebo - Cancer | Phase 3 | Terminated | University of South Florida | 22 | 2010-06-01 | 2015-07-02 |
| AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-02-01 | 2018-06-29 |
| BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors BI 2536, high performance liquid chromatography, mass spectrometry - Breast Cancer, Endometrial Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 76 | 2007-07-01 | 2013-10-07 |
| Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas sunitinib malate - Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 53 | 2007-04-01 | 2016-01-20 |
| Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma perifosine - Endometrial Cancer, Sarcoma | Phase 2 | Completed | NCIC Clinical Trials Group | 17 | 2003-06-09 | 2023-08-04 |
| Mifepristone for Patients With Endometrial Cancer and LGESS Mifepristone - Endometrial Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 13 | 2001-09-01 | 2012-07-30 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Imatinib mesylate - Life Threatening Diseases | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2001-02-01 | 2016-11-18 |
| Thalidomide in Treating Patients With Gynecologic Sarcomas thalidomide - Endometrial Cancer, Sarcoma | Phase 2 | Completed | New York University Cancer Institute | 2000-09-01 | 2013-06-21 | |
| STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma imatinib mesylate - Endometrial Cancer, Gastrointestinal Stromal Tumor | Phase 1 / Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 91 | 2000-08-01 | 2012-09-24 |
| Chemotherapy in Treating Patients With Sarcoma of the Uterus pegylated liposomal doxorubicin hydrochloride - Endometrial Cancer, Sarcoma | Phase 2 | Completed | Gynecologic Oncology Group | 2000-05-01 | 2013-06-10 |
Showing 20 of 27. Sign in to see all of them.
Sarcoma, Endometrial Stromal (22) · Sarcoma (16) · Endometrial Neoplasms (14) · Leiomyosarcoma (13) · Liposarcoma (12) · Fibrosarcoma (11) · Hemangiosarcoma (11) · Neurofibrosarcoma (11) · Histiocytoma, Malignant Fibrous (10) · Sarcoma, Synovial (10) · Ovarian Neoplasms (9) · Malignant mesenchymal tumor (8) · Rhabdomyosarcoma (8) · Hemangiopericytoma, Malignant (7) · Sarcoma, Alveolar Soft Part (7)
Female Urogenital Diseases (27) · Female Urogenital Diseases and Pregnancy Complications (27) · Genital Diseases (27) · Genital Diseases, Female (27) · Genital Neoplasms, Female (27) · Neoplasms by Histologic Type (27) · Neoplasms, Connective and Soft Tissue (27) · Urogenital Diseases (27) · Urogenital Neoplasms (27) · Uterine Diseases (27) · Uterine Neoplasms (27) · Neoplasms (26) · Neoplasms, Complex and Mixed (22) · Neoplasms, Connective Tissue (19)
Doxorubicin (3) · Ifosfamide (3) · Filgrastim (2) · Imatinib Mesylate (2) · Radiotherapy (2) · Anastrozole (1) · Aromatase Inhibitors (1) · BI 2536 (1) · Biopsy (1) · Chemotherapy, Adjuvant (1) · Chromatography, High Pressure Liquid (1) · Cyproheptadine (1) · Fulvestrant (1) · High-Energy Shock Waves (1) · Injections (1)
European Organisation for Research and Treatment of Cancer - EORTC (6) · Gynecologic Oncology Group (3) · Novartis Pharmaceuticals (2) · Centre Leon Berard (1) · Dana-Farber Cancer Institute (1) · Frederic Amant (1) · HRYZ Biotech Co. (1) · Herbert Irving Comprehensive Cancer Center (1) · Italian Sarcoma Group (1) · Lei Li (1) · M.D. Anderson Cancer Center (1) · Medical University of Graz (1) · Memorial Sloan Kettering Cancer Center (1) · NCIC Clinical Trials Group (1) · NYU Langone Health (1)
United States (12) · Canada (6) · Belgium (5) · France (4) · Italy (4) · Netherlands (4) · United Kingdom (3) · Austria (2) · China (2) · Denmark (2) · Germany (2) · Slovakia (2) · Spain (2) · Sweden (2) · Switzerland (2)
A.N. Van Geel, MD (1) · Albiruni Razak, M.D. (1) · Axel Le Cesne, MD (1) · Edgar Petru, MD (1) · Elizabeth A. Eisenhauer, MD (1) · Franco M. Muggia, MD (1) · Gavin C.E. Stuart, MD (1) · Gregory P. Sutton, MD (1) · Jacob Verweij, MD, PhD (1) · Jeffrey P. Krischer, PhD (1) · Kathleen Moore (1) · Laurence H. Baker, DO, FACOI (1) · Lei Li, M.D. (1)
PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 15721421, PMID 16528479, PMID 18378136, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 22954508
U10CA180868 (2), 2017 (1), N01CM62203 (1), P30CA008748 (1), U10CA027469 (1), U10CA081920 (1)